Viewing Study NCT04579120


Ignite Creation Date: 2025-12-25 @ 4:23 AM
Ignite Modification Date: 2025-12-26 @ 3:25 AM
Study NCT ID: NCT04579120
Status: RECRUITING
Last Update Posted: 2024-07-17
First Post: 2020-08-12
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
Sponsor: Tammie L. S. Benzinger, MD, PhD
Organization:

Study Overview

Official Title: Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
Status: RECRUITING
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: HASD_PIB_IND
Brief Summary: To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).
Detailed Description: The purpose of this research study is to evaluate the structure and function of the brain in healthy aging and early Alzheimer's disease using positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT) imaging. The study involves imaging the brain to detect the presence of amyloid deposits (plaques in the brain). Amyloid is a protein that may be related to dementia of Alzheimer's disease (DAT).

This study will use radioactive tracers called C-11 Pittsburgh Compound B (PIB) and F 18/ AV-1451 (Flortaucipir) which binds to beta amyloid and tau in the brain. These compounds are considered investigational, which means that they have not been approved by the United States Food and Drug Administration (FDA).

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: